Cargando…

Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer

BACKGROUND: FOLFIRI regimen, which is composed of 5-FU, Leucovorin, and Irinotecan, is used in the first-line chemotherapy of metastatic colorectal cancer. Irinotecan life threatening toxicity is partly related to cytotoxic drug metabolite which is primarily inactivated by the UGT1A1 enzyme. The pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emami, AH, Sadighi, S, Shirkoohi, R, Mohagheghi, MA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747407/ https://www.ncbi.nlm.nih.gov/pubmed/29072417 http://dx.doi.org/10.22034/APJCP.2017.18.10.2803

Ejemplares similares

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
por: Glimelius, B, et al.
Publicado: (2011)

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
por: Sadighi, Sanambar, et al.
Publicado: (2006)

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2010)

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
por: Minichmayr, Iris K., et al.
Publicado: (2021)

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
por: Zarate, R, et al.
Publicado: (2010)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
por: Seymour, Matthew T, et al.
Publicado: (2013)

The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes
por: Behrouzi, Bita, et al.
Publicado: (2021)

Pharmacogenomics of chemotherapeutic susceptibility and toxicity
por: Moen, Erika L, et al.
Publicado: (2012)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

Irinotecan toxicity: genes or intestinal microflora?
por: Brandi, G, et al.
Publicado: (2009)

Pharmacogenomics: The Genomics of Drug Response
por: March, Ruth
Publicado: (2000)

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
por: Menden, Michael P., et al.
Publicado: (2019)

Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results
por: Di Francia, Raffaele, et al.
Publicado: (2017)

Pharmacogenomics of cardiovascular drugs
por: Adithan, C
Publicado: (2014)

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
por: Ichikawa, W, et al.
Publicado: (2015)

Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer
por: Farajihaye Qazvini, Fatemeh, et al.
Publicado: (2019)

A pharmacogenomic method for individualized prediction of drug sensitivity
por: Cohen, Adam L, et al.
Publicado: (2011)

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
por: Al-Mahayri, Zeina N., et al.
Publicado: (2020)

Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity
por: McEvoy, L., et al.
Publicado: (2021)

Temporal offset association between the number of irinotecan-related adverse reactions and pharmacogenomic studies: A cross-correlation analysis
por: Kong, Lingti, et al.
Publicado: (2023)

Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer
por: Sun, Xinrong, et al.
Publicado: (2017)

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
por: Herzog, J., et al.
Publicado: (2016)

Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies
por: Altena, Renske, et al.
Publicado: (2022)

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
por: Martinez-Balibrea, E, et al.
Publicado: (2010)

Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan
por: Gao, Yiqiao, et al.
Publicado: (2019)

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer
por: Makondi, Precious Takondwa, et al.
Publicado: (2017)

Pharmacogenomic testing and antidepressant response: problems and promises
por: Smith, Tawny L., et al.
Publicado: (2020)

How to find the right drug for each patient? Advances and challenges in pharmacogenomics
por: Kalamara, Angeliki, et al.
Publicado: (2018)

Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer
por: Tam, V.C., et al.
Publicado: (2009)

Pharmacogenomics of adverse drug reactions
por: Daly, Ann K
Publicado: (2013)

Pharmacogenomics of GPCR Drug Targets
por: Hauser, Alexander S., et al.
Publicado: (2018)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: Riera, Pau, et al.
Publicado: (2020)

Demographic Characteristics, Survival and Prognostic Factors of Early Breast Cancer Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cohort Study
por: Behrouzi, Bita, et al.
Publicado: (2017)

Precision in Oncology; a Future Prospect
por: Shirkoohi, Reza
Publicado: (2018)

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
por: Bruun, Jarle, et al.
Publicado: (2018)

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer
por: Takahashi, Shin, et al.
Publicado: (2021)

Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN(®) System Comprehensive Approach
por: Roberto, Michela, et al.
Publicado: (2021)

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
por: Chau, I, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_kicj2d9c0kttgvkgegp4rsgfts